Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Clinical trial NCT03047213 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03047213
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Bladder Urothelial Carcinoma Metastatic Transitional Cell Carcinoma Metastatic Urothelial Carcinoma Recurrent Bladder Carcinoma Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 Stage IV Bladder Urothelial Carcinoma AJCC v7

Start date: 2017-08-24
Primary completion: 2020-10-06
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.